BMO Capital Initiates Coverage on Flexion Therapeutics Inc to Outperform

BMO Capital Initiates Coverage on Flexion Therapeutics Inc(NASDAQ:FLXN). The shares have been rated Outperform. The rating by BMO Capital was issued on Jun 29, 2016.

In a different note, On May 3, 2016, Wells Fargo said it Assumes its rating on Flexion Therapeutics Inc. The shares have been rated ‘Outperform’ by the firm.

Flexion Therapeutics Inc (FLXN) made into the market gainers list on Fridays trading session with the shares advancing 2.91% or 0.435 points. Due to strong positive momentum, the stock ended at $15.4, which is also near the day’s high of $15.4706. The stock began the session at $14.99 and the volume stood at 5,19,167 shares. The 52-week high of the shares is $29.09 and the 52 week low is $7.56. The company has a current market capitalization of $332 M and it has 2,15,70,395 shares in outstanding.

Flexion Therapeutics Inc(FLXN) last announced its earnings results on May 12, 2016 for Fiscal Year 2016 and Q1.Earnings per share were $-0.78. Analysts had estimated an EPS of $-0.59.

Several Insider Transactions has been reported to the SEC. On Jun 22, 2016, Samuel D Colella (director 10% owner) purchased 25,504 shares at $13.74 per share price.Also, On Jun 16, 2016, C Ann Merrifield (director) purchased 1,000 shares at $13.39 per share price.On May 23, 2016, Michael D. Clayman (CEO) purchased 2,000 shares at $10.40 per share price, according to the Form-4 filing with the securities and exchange commission.

Flexion Therapeutics Inc. is a specialty pharmaceutical company focused on the development and commercialization of injectable pain therapies. The Company is also focused on anti-inflammatory and analgesic therapies for the treatment of patients with musculoskeletal conditions such as osteoarthritis (OA) a type of degenerative arthritis. The Company’s portfolio of product candidates addresses the OA pain treatment spectrum from moderate to severe pain. The Company’s products include FX006 which is indicated for front line intra-articular (IA) therapy for patients with moderate to severe OA pain; FX007 which is indicated for post-operative pain and FX005 which is indicated for end-stage OA pain. The Company is conducting a pivotal Phase IIb clinical trial of FX006. The Company is conducting preclinical local pharmacology and toxicology experiments of FX007. FX005 has completed its Phase IIa trials.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *